Abstract
Escherichia coli is one of the main nosocomial pathogens. Recently antibiotic resistance of the pathogen has grown considerably. During our study resistance of 388 nosocomial E. coli isolated in intensive care units (ICUs) different regions of Russia in 2002–2004 and 124 strains isolated in 2006–2008 was studied. Amikacin, amoxicillin/ clavulanic acid, ampicillin, cefepime, cefoperazone, cefoperazone/sulbactam, cefotaxime, cefotaxime/clavulanic acid, ceftazidime, ceftriaxone, ciprofloxacin, co-trimoxazole, doripenem, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, meropenem, moxifloxacin, netilmicin, piperacillin, piperacillin/tazobactam, ticarcillin/clavulanic acid were tested. Carbapenems (imipenem, meropenem, ertapenem, doripenem) showed the maximal activity with 0–0.5% resistant strains. Production of extended spectrum β-lactamases was seen in 49.7% strains in 2002–2004 and 76.6% strains in 2006–2008.
-
1.
Sweeney N. J., Klemm P., McCormick B.A., et al. The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine. Infect Immun 1996; 64:3497-503.
-
2.
McBean M., Rajamani S. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986- 1997. J Infect Dis 2001; 183:596-603.
-
3.
Gransden W., Eykyn S., Phillips I., Rowe B. Bacteremia due to Escherichia coli: A study of 861 episodes. Rev Infect Dis 1990; 12:1008-18.
-
4.
Roberts F., Geere I., Coldman A. A three-year study of positive blood cultures, with emphasis on prognosis. Rev Infect Dis 1991; 13:34–46.
-
5.
Vastag B. New vaccine decreases rate of nosocomial infections. JAMA 2001; 285:1565.
-
6.
Siegman-Igra Y., Fourer B., Orni-Wasserlauf R., et al. Reappraisal of comminity-acquired bacteremia: A proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002; 34:1431–39.
-
7.
Russo T., Johnson J. Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlooked epidemic. Microbes and Infect 2003;5:449–56.
-
8.
Minino A., Smith B. Deaths: Preliminary data for 2000. National Vital Statistics Reports 2001; 49:1–40.
-
9.
Fluit A., Schmitz F., Verhoef J., Group ESP. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001; 20:188–91.
-
10.
Bernard G., Vincent J., Laterre P., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
-
11.
Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289: 885-8.
-
12.
Kramer A., Schwebke I., Kampf1 G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases 2006, 6:130.
-
13.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
-
14.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document M100-S16. 2008. Clinical and Laboratory Standards Institute, Wayne, PA.
-
15.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 13th informational supplement. NCCLS document M100-S13 2003. National Committee for Clinical Laboratory Standards, Wayne, PA.
-
16.
Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». 2004.
-
17.
Garcia-Rodriguez J.-A., Jones R.N. and the MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Prorgramme. J Chemother 2002; 14:25-32.
-
18.
Rhomberg P.R., Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57:207- 215.
-
19.
Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352-9.
-
20.
Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60:1018-29.
-
21.
Hoban D., Bouchillon S., Johnson B., et al. Tigecylcine in vitro activity in current European pathogens - T.E.S.T. Programm 2006. Abstract P490. In: Programs and Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 2006.
-
22.
Cermak P., Kolar M., Latal T. Frequency of gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. Intern J Antimicrob Agents 2004; 23:401-404.
-
23.
Nijssen S., Florjin A., Bonten M.J.M., Schmitz F.J., Verhoef J., Fluit A.C. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24:585-591.
-
24.
Streit J.M., Jones R.N., Sader H.S., Fritshce T.R. Assessment of pathogen occurrence and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Programm (North America, 2001). Int J Antimicrob Agents 2004; 24: 111-8.
-
25.
Livermore D.M., Canton R., Gniadkowski M., et al. CTXM: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165-74.
-
26.
Эйдельштейн М.В., Страчунский Л.С., исследовательская группа РОСНЕТ. Динамика распространённости и чувствительности БЛРС–продуцирующих энтеробактерий к различным антимикробным препаратам в ОРИТ России. Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(4):323-36.
-
27.
Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001- 2004). Clin Microbiol Infect 2006; 12:315-21.